Vistin Pharma ASA : Final result of the subsequent repair issue

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. PLEASE SEE THE IMPORTANT INFORMATION AT THE END OF THE ANNOUNCEMENT

Oslo, 28 May 2018: Reference is made to the stock exchange announcements dated 9 May 2018 and 14 May 2018 regarding the subsequent repair issue of up to 4,464,286 new shares (the "Offer Shares") in Vistin Pharma ASA ("Vistin Pharma" or the "Company") at a subscription price of NOK 11.20 per share (the "Subsequent Repair Issue").

The subscription period in the Subsequent Repair Issue expired on 25 May at 16:30 CEST. By the end of the subscription period, the Company had received valid subscriptions for a total of 503,942 offer shares. Hence, 503,942 Offer Shares will be issued. All subscribers have received full allocation.

Notifications of allocated offer shares in the Subsequent Repair Issue and the corresponding amount to be paid by each subscriber will be set out in a separate letter to each subscriber to whom shares have been allotted. The allocation letters are expected to be sent on 28 May 2018.

The share capital increase relating to the Subsequent Repair Issue is expected to be registered with the Norwegian Register of Business Enterprises on or about 31 May 2018 and that the shares will be delivered to the VPS accounts of the subscribers to whom they are allocated and listed on Oslo Børs on or about the 1 June 2018.

DNB Markets, a part of DNB Bank ASA, is acting as Manager for the Subsequent Repair Issue.

This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

For further information, please contact:

Gunnar Manum
CFO
+47 951 79 190